Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells. 2013

M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
SERGAS, Santiago University Clinical Hospital Research Laboratory 9 (NEIRID LAB: Laboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Institute of Medical Research (IDIS), Santiago de Compostela, 15706, Spain.

Multiple myeloma (MM) is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the bone marrow milieu. MM is the second of all hematological malignancies. Thus, the search for new pharmacological weapons is under intensive investigation being MM a critically important public health goal. Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1 α) is crucially involved in the development of osteolytic bone lesions in MM. Phenolic components of extra virgin olive oil are reported to have anti tumor activity. However, the underlying mechanisms and specific targets of extra virgin olive oil remain to be elucidated. In the present study, we investigated the effects of a recently isolated novel extra virgin olive oil polyphenol, oleocanthal, on the human multiple myeloma cell line ARH-77. Here we report that this natural compound has a remarkable in vitro activity by inhibiting MIP-1 α expression and secretion in MM cells. In addition, we also demonstrated that oleocanthal inhibits MM cells proliferation by inducing the activation of apoptosis mechanisms and by down-regulating ERK1/2 and AKT signal transduction pathways. This in vitro study suggests a therapeutic potential of oleocanthal in treating multiple myeloma.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D010938 Plant Oils Oils derived from plants or plant products. Oils, Plant,Oils, Vegetable,Plant Oil,Vegetable Oil,Vegetable Oils,Oil, Plant,Oil, Vegetable
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069463 Olive Oil Oil extracted from fruit of the OLIVE TREE (genus Olea). Olive Oils,Oil, Olive,Oils, Olive
D000081004 Cyclopentane Monoterpenes Monoterpenes that include a cyclopentane ring in their structure. Monoterpenes, Cyclopentane
D000447 Aldehydes Organic compounds containing a carbonyl group in the form -CHO. Aldehyde
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
November 2021, Acta biochimica et biophysica Sinica,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
March 2019, Die Pharmazie,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
January 2016, BioMed research international,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
September 2017, Molecular medicine reports,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
March 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
December 2017, Zhongguo shi yan xue ye xue za zhi,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
December 2003, BMC cell biology,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
October 2022, Oncotarget,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
September 2000, Leukemia & lymphoma,
M Scotece, and R Gómez, and J Conde, and V Lopez, and J J Gómez-Reino, and F Lago, and A B Smith, and O Gualillo
January 2001, Blood,
Copied contents to your clipboard!